LomitapideMeSH concept

https://ansm.sante.fr/tableau-marr/lomitapide
2025
false
false
false
France
French
risk management
lomitapide
lomitapide
patient education handout
guideline
drug interactions
anticholesteremic agents
lomitapide
anticholesteremic agents
administration, oral

---
https://www.has-sante.fr/jcms/p_3505740/fr/lojuxta-lomitapide-hypercholesterolemie-familiale-homozygote
2024
false
false
false
France
Lomitapide Mesylate
Homozygous Familial Hypercholesterolemia
child
adolescent
evaluation of the transparency committee
lomitapide
Lomitapide Mesylate
mesylates

---
http://www.has-sante.fr/portail/jcms/c_2048964/fr/lojuxta
2015
false
France
French
evaluation of the transparency committee
lomitapide
lomitapide
lomitapide
administration, oral
insurance, health, reimbursement
treatment outcome
BMS201038
BMS201038
anticholesteremic agents
anticholesteremic agents
hyperlipoproteinemia type ii
hyperlipoproteinemia type ii
Familial hypercholesterolemia - homozygous (disorder)
adult
drug therapy, combination
genetic testing
benzimidazoles
benzimidazoles

---
Summary Basis of Decision (SBD) for Juxtapid
Lomitapide mesylate, 5 mg, 10 mg and 20 mg, capsule, oral
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00224
2014
false
Canada
French
English
lomitapide
lomitapide
lomitapide
administration, oral
drug approval
canada
Familial hypercholesterolemia - homozygous (disorder)
hyperlipoproteinemia type ii
BMS201038
BMS201038
adult
anticholesteremic agents
anticholesteremic agents
rare diseases
drug interactions
treatment outcome
clinical trials, phase iii as topic
Lomitapide Mesylate
microsomal triglyceride transfer protein
carrier proteins
benzimidazoles
benzimidazoles
drug information

---
http://www.has-sante.fr/portail/jcms/c_1719428/fr/lojuxta-lomitapide-hypocholesterolemiant
2014
false
false
false
France
French
lomitapide
lomitapide
lomitapide
Lomitapide Mesylate
administration, oral
anticholesteremic agents
anticholesteremic agents
Familial hypercholesterolemia - homozygous (disorder)
hyperlipoproteinemia type ii
treatment outcome
adult
drug therapy, combination
rare diseases
clinical trials, phase iii as topic
insurance, health, reimbursement
guidelines for drug use
evaluation of the transparency committee
BMS201038
BMS201038
benzimidazoles
benzimidazoles

---
https://www.ema.europa.eu/medicines/human/EPAR/Lojuxta
2013
false
United Kingdom
English
French
lomitapide
lomitapide
lomitapide
drug approval
europe
treatment outcome
adult
administration, oral
hyperlipoproteinemia type ii
anticholesteremic agents
anticholesteremic agents
summary of product characteristics
package leaflet
drug evaluation
syndication feed
BMS201038
BMS201038
continuity of patient care
drug interactions
breast feeding
pregnancy
drug evaluation, preclinical
microsomal triglyceride transfer protein
carrier proteins
benzimidazoles
benzimidazoles

---